fluvoxamine maleate

Also found in: Dictionary.

fluvoxamine maleate

Apo-Fluvoxamine (CA), Co Fluvoxamine (CA), Dom-Fluvoxamine (CA), Faverin (UK), Luvox CR, Novo-Fluvoxamine (CA), Nu-Fluvoxamine (CA), PHL-Fluvoxamine (CA), PMS-Fluvoxamine (CA), Ratio-Fluvoxamine (CA), Riva-Fluvoxamine (CA), Sandoz Fluvoxamine (CA)

Pharmacologic class: Selective serotonin reuptake inhibitor (SSRI)

Therapeutic class: Antidepressant, antiobsessive agent

Pregnancy risk category C


Selectively inhibits serotonin reuptake in neurons. This inhibition is thought to relieve depression and reduce behaviors related to obsessive-compulsive disorder (OCD).


Capsules (extended-release): 100 mg, 150 mg

Tablets: 25 mg, 50 mg, 100 mg

Indications and dosages


Adults: Initially, 50 mg P.O. daily at bedtime; may increase by 50 mg q 4 to 7 days until desired effect occurs (not to exceed 300 mg/day). If daily dosage exceeds 100 mg, give in two equally divided doses; if doses aren't equal, give larger dose at bedtime. As needed, adjust dosage periodically to maintain lowest effective dosage that controls symptoms (immediate-release formulation)

Children ages 8 to 17: Initially, 25 mg at bedtime; may increase by 25 mg/day q 4 to 7 days until desired effect occurs (up to 200 mg/day for patients up to age 11 or up to 300 mg for adolescents). If daily dosage exceeds 50 mg, give in divided doses, with larger dose at bedtime (immediate-release formulation).

OCD; social anxiety disorder

Adults: 100 mg P.O. once daily at bedtime; titrate in 50-mg increments weekly, to a maximum of 300 mg/day (extended-release formulation).

Dosage adjustment

• Hepatic impairment

• Elderly patients

Off-label uses

• Autism

• Anxiety disorders


• Hypersensitivity to drug or other SSRIs

• MAO inhibitor use within past 14 days


Use cautiously in:

• cardiovascular disease, hepatic or renal impairment, mania, seizures, suicidal tendency

• elderly patients

• labor and delivery

• pregnant or breastfeeding patients.


• Give with or without food.

• Discontinue 5 weeks before MAO inhibitor therapy is set to begin.

Adverse reactions

CNS: dizziness, drowsiness, headache, insomnia, nervousness, anxiety, apathy, manic or psychotic reactions, depression, hypokinesia or hyperkinesia, tremor, suicide or suicidal ideation (especially in child or adolescent)

CV: hypertension, orthostatic hypotension, palpitations, tachycardia

EENT: sinusitis

GI: nausea, vomiting, diarrhea, constipation, dyspepsia, flatulence, dry mouth, dysphagia, anorexia

GU: decreased libido, sexual dysfunction, anorgasmia

Musculoskeletal: hypertonia, myoclonus, twitching

Respiratory: cough, dyspnea

Skin: diaphoresis

Other: abnormal taste, tooth disorder, dental caries, edema, weight gain or loss, chills, fever, flulike symptoms, yawning, hot flashes, allergic reactions, hypersensitivity reaction


Drug-drug. Beta-adrenergic blockers (such as propranolol), carbamazepine, lithium, L-tryptophan, methadone, some benzodiazepines, theophylline, tolbutamide, warfarin: decreased fluvoxamine metabolism, increased effects

Clozapine: increased clozapine blood level and risk of toxicity

MAO inhibitors: serotonin syndrome

Tricyclic antidepressants: increased fluvoxamine blood level

Drug-tests. Hepatic enzyme levels: increased

Drug-behaviors. Smoking: decreased fluvoxamine efficacy

Patient monitoring

Watch closely for signs and symptoms of depression and suicidal ideation (especially in child or adolescent).

• Assess patient's appetite. Report weight gain or loss.

• Monitor liver function test results.

• Monitor cardiovascular status, particularly blood pressure.

Patient teaching

• Instruct patient to swallow extended-release capsules whole and not to break, crush, or chew them.

Instruct patient or caregiver (especially with child or adolescent patient) to recognize and immediately report signs of suicidal intent or expressions of suicidal ideation.

• Inform patient that drug may take several weeks to be fully effective.

• Recommend establishing effective bedtime routine to minimize insomnia.

• Instruct female patient to notify prescriber if she becomes or intends to become pregnant. Caution her not to breastfeed.

• Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.

• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and behaviors mentioned above.

fluvoxamine maleate

an antidepressant drug with selective inhibitory action in neuronal serotonin reuptake.
indications It is prescribed in the treatment of obsessive-compulsive disorder in adult patients and has unlabeled uses for treating depression and panic attacks in adults, and anxiety in children.
contraindications It should not be given to patients with allergy to fluvoxamine maleate, patients who use monoamine oxidase inhibitors, or patients with a history of seizures, suicide attempts, or mania.
adverse effects The side effects most often reported include headache, sleepiness or insomnia, nausea, vomiting, and sexual dysfunction.

fluvoxamine maleate (flōōvak´səmēn´ mā´lēāt),

n brand name: Luvox;
drug class: antidepressant;
action: selectively inhibits reuptake of serotonin in central nervous system neurons;
uses: obsessive-compulsive disorder.
References in periodicals archive ?
Par Pharmaceutical Companies, a generic pharmaceutical company in the United States, has received approval for its abbreviated new drug application for fluvoxamine maleate 100mg and 150mg extended-release capsules from the United States Food and Drug Administration, it was reported on Friday.
Par Pharmaceutical Companies was awarded 180 days of marketing for fluvoxamine maleate 150mg ER capsules.
Fluvoxamine maleate is a selective serotonin reuptake inhibitor, which was originally developed in Switzerland in 1983 and has been marketed in Japan since 1999.
This is the world's first such indication approved for fluvoxamine maleate.
announced today a product license agreement under which Jazz Pharmaceuticals will have the right to market LUVOX([R]) (fluvoxamine maleate) Tablets and fluvoxamine maleate extended-release capsules, upon approval by the Food and Drug Administration (FDA), in the United States.
Most recently, Solvay Pharmaceuticals submitted a New Drug Application (NDA) in April 2006 to the FDA for fluvoxamine maleate extended-release capsules, an investigational compound being studied for the treatment of generalized social anxiety disorder (SAD) and obsessive compulsive disorder (OCD) in adults.
The company has also received clearance for fluvoxamine maleate 25, 50 and 100 mg tablets USP, the equivalent to Luvox, indicated for the treatment of obsessive compulsive disorder.
announced that the Food and Drug Administration approved Synthon's abbreviated new drug application (ANDA) on January 17 for fluvoxamine maleate tablets in 25 mg, 50 mg and 100 mg strengths.
Fluvoxamine maleate is the generic equivalent to Solvay Pharmaceuticals' Luvox(R) tablets, which are indicated for the treatment of obsessions and compulsions in patients with obsessive compulsive disorder.
Food and Drug Administration to market Fluvoxamine Maleate 25mg, 50mg and 100mg Tablets.
NYSE:MYL) announced today that the Food and Drug Administration has approved Mylan's abbreviated new drug application (ANDA) for Fluvoxamine Maleate Tablets in 25 mg, 50 mg, and 100 mg strengths.